DaVita

DaVita Book Value per Share

The Book Value per Share of DaVita (DVA) as of Nov 12, 2026 is 15.27 USD. In the previous year, Book Value per Share was 27.56 USD — a change of -44.61% (lower).

Book Value per Share

15.27USD

YoY

-44.61%

Last updated:

Book Value per Share of DaVita is 2025 15.27 USD. Book Value per Share of DaVita was 2024 27.56 USD. It decreases by -44.61% lower compared to the previous year.

The DaVita Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
66.32 USD
Jan 1, 2019
46.12 USD
Jan 1, 2020
38.17 USD
Jan 1, 2021
31.24 USD
Jan 1, 2022
29.32 USD
Jan 1, 2023
36.15 USD
Jan 1, 2024
27.56 USD
Jan 1, 2025
15.27 USD
The DaVita Book Value per Share history
YEARBook Value per ShareYoY
15.27USD-44.61%
27.56USD-23.77%
36.15USD+23.31%
29.32USD-6.17%
31.24USD-18.15%
38.17USD-17.23%
46.12USD-30.47%
66.32USD-14.66%
77.72USD+1.28%
76.73USD-2.11%
78.38USD-3.91%
81.57USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DaVita Stock analysis

What does DaVita do? DaVita Inc. is a company headquartered in Denver, Colorado, specializing in the provision and management of outpatient dialysis treatments (renal replacement therapy) and related services. The company was founded in 1999 and has since experienced impressive growth, with a presence in over ten countries worldwide. The history of DaVita traces back to the origin of its business model: outpatient dialysis treatment. This is a form of renal replacement therapy where patients can be treated outside of the hospital, in a dedicated center or even in their own homes. This type of dialysis is less intimidating compared to inpatient treatment in a hospital and can be much more flexible in terms of scheduling. DaVita took this idea and brought it to the market in the US and other countries, where it has proven to be extremely successful. Nowadays, DaVita operates in three main business segments. The first is the patient care segment, which focuses on providing dialysis treatments and related services. Here, DaVita offers outpatient dialysis centers where patients can receive regular treatment. Another important aspect of this segment is patient and family education, integrating them into the treatment process and helping them lead as normal a life as possible. The second core area is the pharmaceutical supply business. DaVita has an extensive network of facilities and suppliers, as well as its own pharmacies where the necessary medications for dialysis patients are manufactured and stored. DaVita also handles billing with insurance and other payment entities to ensure seamless patient care. The third core area of DaVita is the international supply company. Here, DaVita offers its services in over ten countries worldwide, including Mexico, Colombia, Brazil, Saudi Arabia, and Canada. DaVita has steadily expanded its international business in recent years and aims to have a presence in even more countries in the future. But DaVita does not limit itself to these three core areas. The company is also known for its innovative research and development efforts aimed at improving the treatment of kidney disease and developing new technologies. Products offered by DaVita include innovative dialysis devices, advanced care management software, and intelligent sensors for automated patient monitoring. In its over 20-year history, DaVita has overcome many challenges, including regulatory issues, economic fluctuations, and ever-growing competition. Despite these challenges, the company has steadily expanded its position in the industry and established itself as a leading provider of dialysis and related services. DaVita's success is based on a culture of results orientation and a strong commitment to improving patient outcomes. The company understands that each patient has unique needs and that the treatment of kidney disease requires a lifelong commitment. Therefore, DaVita emphasizes individual care and collaboration with patients and their families to ensure optimal care. Overall, DaVita is an innovative company specializing in the provision of dialysis treatments and related services. The company has overcome many challenges in its history and established itself as a leading provider of dialysis and related services. DaVita is committed to improving the quality of life for dialysis patients worldwide and continuously optimizing the treatment of kidney disease. DaVita is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DaVita stock

Book Value per Share of DaVita is 15.27 USD in 2025.

Book Value per Share of DaVita changed from 27.56 USD to 15.27 USD, representing a -44.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share DaVita since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — DaVita

All Key Metrics — DaVita